Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest From Alaric DeArment

AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds

A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.

Artificial Intelligence Business Strategies

FDA Leaves Door Open For Further Discussions With Agenus Over BOT/BAL

The biotech company surprised observers when it announced the agency advised against filing for accelerated approval of the CTLA-4/PD-1 combination.

FDA Business Strategies

Relay’s SHP2 Runs Aground As Roche Pulls Out Of Development Deal

Relay said in an SEC filing that Roche terminated the deal to develop migoprotafib, though Roche emphasized that it was not due to any emerging clinical safety concerns.

Deals Business Strategies

Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor

The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.

Financing Business Strategies

Cautious Optimism Greets Lexeo’s LX2006 For Friedreich’s Ataxia

The company’s shares fell amid debate over improvements in LVMI, but an analyst pointed out that they indicated the gene therapy has efficacy in Friedreich ataxia cardiomyopathy.

Clinical Trials Gene Therapy

How The IRA Factored Into Akebia’s Price For Vafseo

Akebia says its price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.

Medicare Renal
See All
UsernamePublicRestriction

Register